Share

Daily SumUp
India Finally Approves Weight Loss Drug Tirzepatide
In a significant development for the healthcare sector, India has officially approved the use of Tirzepatide, a weight loss medication previously hailed for its efficacy in managing obesity. This decision comes after extensive clinical trials demonstrated the drug's effectiveness in promoting significant weight loss among participants.
Tirzepatide, originally developed for type 2 diabetes management, has shown promising results in reducing body weight by acting on multiple pathways involved in appetite regulation. Clinical studies revealed that patients using Tirzepatide lost an average of 15% of their body weight over a 72-week period, making it one of the most effective weight loss drugs available.
The approval follows rigorous evaluation by the Central Drugs Standard Control Organization (CDSCO), which emphasized the drug's potential to combat rising obesity rates in India. Health experts view this move as a crucial step in addressing the growing public health challenge of obesity, which is linked to various chronic diseases, including diabetes and cardiovascular conditions.
Dr. Aditi Sharma, a leading endocrinologist, expressed optimism about the approval, stating, "Tirzepatide could be a game-changer for many individuals struggling with obesity. With the right lifestyle modifications, it can provide a much-needed boost to those looking to manage their weight effectively."
The drug is expected to be available in pharmacies soon, although its cost remains a concern. Initial pricing estimates suggest it may be accessible primarily to those with higher disposable incomes, prompting calls for government interventions to ensure broader availability.
As Tirzepatide becomes available, health officials are urging healthcare providers to offer comprehensive counseling alongside the medication, emphasizing the importance of diet and exercise in achieving sustainable weight loss.
With the approval of Tirzepatide, India joins several other countries that have embraced this innovative approach to weight management, marking a significant milestone in the ongoing fight against obesity and its related health issues.
Give it a Listen💖
News Voiced and Reported by: Zahra
Sources: GOV | BBC
Genre: Geo-Politics | Current Affairs | Health
More episodes
View all episodes

12240. EXCLUSIVE: US Trump claims he'd win as the president of Venezuela, WATCH THIS CLIP
01:37||Season 1, Ep. 12240US Trump claims he'd win as the president of Venezuela....
12239. US Trump lashes out at Pacific allies for not assisting in Iran fight
02:00||Season 1, Ep. 12239Trump lashes out at Pacific allies for not assisting in Iran fight....
12238. NEW reports from inside Iran as time is running out on US Trump's latest deadline
03:03||Season 1, Ep. 12238News reports from inside Iran as time is running out on Trump's latest deadline....
12237. US and Iran in talks over 45-day ceasefire proposal part of two-phase deal
02:05||Season 1, Ep. 12237US and Iran in talks over 45-day ceasefire proposal part of two-phase deal....
12236. Iran threatens to restrict Bab el-Mandeb Strait after US Trump warnings
02:17||Season 1, Ep. 12236Iran threatens to restrict Bab el-Mandeb Strait after US Trump warnings....
12235. EXCLUSIVE: Indonesia Allows Airlines To Raise Fares Up To 13 Percent Amid Fuel Surge
01:57||Season 1, Ep. 12235Indonesia Allows Airlines To Raise Fares Up To 13 Percent Amid Fuel Surge....
12234. Iran-US war live: Ceasefire response ‘not good enough’, says US Trump
02:08||Season 1, Ep. 12234Ceasefire response ‘not good enough’, says Trump....
12241. EXCLUSIVE: US Trump warns journalist: Reveal source of leak or face jail time
01:34||Season 1, Ep. 12241Trump warns journalist: Reveal source of leak or face jail time....
12233. What comes next for US if Iran doesn't reopen Strait of Hormuz?
02:01||Season 1, Ep. 12233What comes next for US if Iran doesn't reopen Strait of Hormuz...